Berobenatide trial for women with urine leakage and obesity enters PHASE3 recruiting — LiveFuture News
Open on LiveFuture.ai →

Berobenatide trial for women with urine leakage and obesity enters PHASE3 recruiting

Pfizer’s VESPER-SUI study is recruiting women with urine leakage and obesity or overweight, using a randomized berobenatide-versus-placebo design with a Week 52 incontinence measure.

A new phase 3 study is now recruiting women with urine leakage and obesity or overweight, and that matters because it points to another large clinical test in a condition that can affect everyday life. The trial is called VESPER-SUI, and its current status is RECRUITING as of 2026-11-19T00:00:00+00:00. It is a ClinicalTrials.gov registry observation, not a results report.

The study is sponsored by Pfizer and uses a randomized design with two arms: Berobenatide in Arm 1 and Placebo in Arm 2. Its primary outcome is change from baseline in Stress Incontinence Episode Frequency (IEF), measured from Baseline to Week 52. Because has_results is false, the registry entry shows the setup of the study, not the answer to whether the drug works.

What the study is testing

Berobenatide is the drug being evaluated, and the comparison against placebo is meant to show whether there is a meaningful difference in stress incontinence episode frequency over time. The trial title makes the target group clear: women with urine leakage and with obesity or overweight. The study is described as being in PHASE3, which means it is at a later stage of testing than early safety work.

The estimated primary completion date is 2028-10-13, so this is still a long-running trial rather than a near-term readout. That makes the current recruiting status especially important for readers who are tracking how obesity-linked research is expanding across different health problems.

Why it fits the wider obesity-and-metabolic theme

This trial sits naturally alongside other obesity-related registry observations in the same live special event, including studies on exercise, diet, metabolic change, and cardiometabolic health. Together, those records show that research activity is not limited to weight itself; it also reaches related conditions and quality-of-life concerns.

The special event page for Obesity & Metabolic provides the broader context for this study and for other current registry observations with the same shared topic. In practical terms, that means VESPER-SUI is part of a larger stretch of active research focused on how excess weight connects to different health outcomes, from metabolism to daily symptoms.

What readers should watch next

For now, the most useful update is simple: the study is recruiting, it has no posted results, and the main comparison is Berobenatide versus placebo. Any future change in status or results posting would be the next meaningful signal.

Until then, the registry entry offers a clean snapshot of the trial’s design, target population, and timeline. For readers following obesity-related research, it is another sign that the field continues to broaden into conditions that may not always be the first ones people associate with weight management.